Brief: Ascentage Pharma Group International Says HY Revenue Rmb142.7 Million
21/08/2023 16:03
Aug 21 (Reuters) - Ascentage Pharma Group International
6855.HK :
* HY REVENUE RMB142.7 MILLION VERSUS RMB95.8 MILLION
* HY LOSS ATTRIBUTABLE RMB402.4 MILLION VERSUS LOSS RMB406.7
MILLION
Source text for Eikon: ID:nHKSbGKyXd
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up